You just read:

Aprea Therapeutics Announces First Patient Enrolled in Phase Ib/II Clinical Study of APR-246 for the Treatment of Platinum-Resistant High-Grade Serous Ovarian Cancer

News provided by

Aprea Therapeutics AB

Aug 02, 2017, 03:00 ET